Rivaroxaban is non-inferior to warfarin in terms of efficacy and safety in the management of patients with atrial fibrillation and a bioprosthetic mitral valve. The Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation (RIVER) trial, published in the NEJM, randomised 1,005 patients to either rivaroxaban (20 mg once daily) or warfarin (adjusted to INR 2.0-3.0). ...
Reassurance on DOACs in AF patients with bioprosthetic valves
By Mardi Chapman
26 Nov 2020